NextCure, Inc. NXTC

NXTC Company Overview

NextCure, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing immunomedicine therapies for cancer and immune-related diseases. The company operates within the biotechnology and oncology drug development industries, with research centered on identifying and targeting immune signaling pathways that regulate the body’s response to tumors. NextCure’s primary revenue sources have historically consisted of collaboration agreements, licensing arrangements, and research funding rather than commercial product sales, as the company does not currently market approved therapies.

The company’s core pipeline has included antibody-based therapeutics designed to modulate immune responses in oncology settings. Its lead development programs have targeted checkpoint biology and tumor microenvironment signaling pathways intended to enhance anti-tumor immune activity. NextCure was founded in 2015 by a team that included immunology researcher Michael Richman and scientists associated with prior oncology and immunotherapy ventures. Since its founding, the company has evolved from discovery-stage research into a clinical-stage organization conducting human trials and strategic collaborations intended to validate its immunotherapy platform.